Dan Liljenquist, Intermountain Health’s chief strategy officer, said that more large health systems should employ a hub-and-spoke model to ensure that rural providers can thrive. Under this model, large health systems partner with rural hospitals — with the rural “spoke” hospitals gaining access to the larger “hub” health system’s technology, staff, medication discounts and more….
Lynx’s Series A round was led by Flare Capital Partners and included participation from CVS Health Ventures, McKesson Ventures, .406 Ventures, Obvious Ventures and Frist Cressey Ventures. The post Lynx Secures $27M To Simplify Healthcare Payments appeared first on MedCity News.
A data safety monitoring board recommended pausing the Phase 2b test of Pliant’s bexotegrast, an experimental treatment for idiopathic pulmonary fibrosis. The move follows a prespecified data review, the company said. The post Pliant Therapeutics Presses Pause on Clinical Trial for Lung Disorder Drug appeared first on MedCity News.
AI can be a highly effective tool for plans aiming to reduce fraud, waste and abuse, but only if it is combined with investigative intelligence. The post AI: A Good Tool to Combat Bad Actors in Healthcare appeared first on MedCity News.
AI-assisted software development can help teams achieve faster delivery, lower costs, and higher-quality results – all key to meeting patients’ and providers’ digital health expectations. The post The Future of Healthcare Apps Depends on AI-Assisted Development appeared first on MedCity News.
CMS recently issued a statement saying that it’s continuing the Medicare Drug Price Negotiation Program but is leaving the door open for potential changes. Experts weighed in on what changes could be made and what changes they would like to see. The post Could the Trump Administration Change the Medicare Drug Price Negotiation Program? appeared…
Sionna Therapeutics found strong investor interest in its cystic fibrosis drugs, which could rival blockbuster Vertex Pharmaceuticals product Trikafta. The biotech has three internally developed programs that hit a target unaddressed by any currently available CF therapies. The post Vertex Pharma Challenger Sionna Secures $191M in IPO Cash for Cystic Fibrosis Pipeline appeared first on…
At a moment when medication therapy for sickle cell disease (SCD) leaves too many behind and widespread access to curative gene therapies still lies in the distant future, automated red blood cell exchange is experiencing renewed interest. To improve patients’ lives, a broad commitment is needed to expand access to transfusion therapies. The post Beyond…
Kennedy emphasized that these inefficiencies aren’t just administrative headaches, they’re costing lives. Nowhere is this more evident than in organ-transplant logistics: the way organs get assigned – and move – from donors to patient recipients. The post RFK’s Hearing: Inefficiencies in Government-Controlled Systems appeared first on MedCity News.
Bain Capital’s buyout of Mitsubishi Tanabe Pharma brings a company with a drug portfolio and pipeline in areas such as immunology, central nervous system disorders, and metabolic disease. This business is the pharmaceuticals division of Japanese conglomerate Mitsubishi Chemical Group. The post Bain Capital Broadens Its Biotech Reach With $3.3B Deal for Mitsubishi Tanabe Pharma…